Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.
作者信息
Dell'Oglio Paolo, Sanchez-Salas Rafael
机构信息
Department of Urology, Institut Mutualiste Montsouris, Paris, France.
Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
出版信息
Int Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi: 10.1590/S1677-5538.IBJU.2017.04.02.
Abstract
摘要
相似文献
1
Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.大多数局限性前列腺癌患者未来都会接受治疗吗？| 观点：是的。
Int Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi: 10.1590/S1677-5538.IBJU.2017.04.02.
2
Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.大多数局限性前列腺癌患者未来都会接受治疗吗？| 观点：不会。
Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03.
3
Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.意见分歧——中危前列腺癌的主动监测：是否安全？意见：是安全的。
Int Braz J Urol. 2016 May-Jun;42(3):413-7. doi: 10.1590/S1677-5538.IBJU.2016.03.03.
4
[Prostate tumors].
Rev Prat. 2002 Jan 15;52(2):207-12.
5
Focal therapy meets prostate cancer.聚焦治疗与前列腺癌相遇。
Lancet. 2010 Sep 25;376(9746):1036-7. doi: 10.1016/S0140-6736(10)60594-6.
6
[Prostate cancer].[前列腺癌]
Praxis (Bern 1994). 2010 Feb 3;99(3):149-56, 158; quiz 157. doi: 10.1024/1661-8157/a000044.
7
[Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].[早期前列腺癌的诊断与治疗。预后改善——并发症减少]
MMW Fortschr Med. 2010 May 13;152(19):36.
8
[Early detection of prostatic carcinoma: Is PSA screening suitable?].[前列腺癌的早期检测：前列腺特异性抗原筛查是否合适？]
Dtsch Med Wochenschr. 2003 May 2;128(18):977.
9
Imaging-guided biopsy detects prostate cancer.
Cancer. 2013 May 15;119(10):1767. doi: 10.1002/cncr.28140.
10
Prostate cancer screening: is it possible to explain diametrically opposed views?
N Z Med J. 2005 Feb 11;118(1209):U1289.
本文引用的文献
1
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.主动监测时代前列腺局灶性治疗的患者选择：一项国际 Delphi 共识项目。
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.
2
Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy.多参数磁共振成像/超声融合引导活检的病理结果：与前列腺癌局部治疗的关系
Urology. 2017 Jul;105:18-23. doi: 10.1016/j.urology.2017.02.027. Epub 2017 Feb 24.
3
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.多参数 MRI 和 TRUS 活检在前列腺癌（PROMIS）中的诊断准确性：一项配对验证性研究。
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.
4
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.PLCO试验中前列腺癌筛查的延长死亡率结果，中位随访时间为15年。
Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.
5
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.局限性前列腺癌监测、手术或放疗 10 年后的结果。
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
6
Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.局部前列腺癌管理中的时间趋势及种族、保险和社会经济地位的影响。
Eur Urol. 2017 May;71(5):729-737. doi: 10.1016/j.eururo.2016.08.047. Epub 2016 Sep 3.
7
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.新方法和成熟技术在前列腺局灶性消融治疗中的应用：系统综述。
Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29.
8
Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.哥德堡随机、基于人群的前列腺癌筛查试验中主动监测的长期结果。
Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.
9
Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.极低风险前列腺癌根治性前列腺切除术后1年的肿瘤学和功能结果：前瞻性LAPPRO试验的结果
BJU Int. 2016 Aug;118(2):205-12. doi: 10.1111/bju.13444. Epub 2016 Mar 18.
10
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.尿液中TMPRSS2:ERG加PCA3用于个体化前列腺癌风险评估。
Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.
Zotero 插件